AB0554 LOW-DOSE IL-2 CHANGED THE PROPRTION OF LYMPHOCYTE SUBSETS IN PATIENTS WITH PRIMARY SJOGREN’S SYNDROME

Background

Primary Sjögren's syndrome (pSS) is a chronic inflammatory autoimmune illness characterized by various immune abnormalities. Abnormalities in the proportions of blood T lymphocyte subtype, that is Th17/Treg, were detected in pSS patients. Interleukin (IL)-2 is a crucial cytokine for tipping the balance of regulatory T(Treg) cells and effector T cells, which can effectively relieve pSS.

Objectives

This study aimed to systematically evaluate the changes in the number of lymphocyte subsets after low-dose IL-2 therapy for pSS.

Methods

Systematic searches of PubMed, EMBASE, Web of Science, the Cochrane Library and Medline, CNKI, CBM, and Technology Journal Database were performed. Original case reports, case series, observational studies, and clinical trials reporting the changes in lymphocyte subsets on pSS patients treated with IL-2 were included. A random-effects meta-analysis was performed to calculate the pooled efficacy. Inconsistency was evaluated by using the I ^[2], and Egger tests were used for the evaluation of potential publication bias (STATA v.12.0)

Results

A total of 3 studies comprising 929 patients were identified(Table 1). The numbers of Th17 cells and Tregs were significantly increased after IL-2 injection [SMD=0.325, 95%CI (0.060,0.590), P=0.016; SMD=1.085, 95%CI(0.469,1.701), P=0.001], while there were no statistical differences in the ratio of Th17/Tregs[SMD=-0.263, 95%CI (-0.602,0.076), P=0.129]between before and after IL-2 treatment(Figure 1).

Conclusion

Low-dose IL-2 was promising in treating pSS, which could promote the proliferation and functional recovery of Tregs and regulate the balance between Treg cells and effector T cells towards Treg cells.

Acknowledgements

This work was supported by the National Natural Science Foundation of China (No. 82001740).

Disclosure of Interests

None Declared.